Drug Trial Radar · NCT04646603
MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients
Last checked: Nov 20, 2026Latest source record: Feb 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
40
Planned (sponsor's estimate)
Start
Dec 1, 2021
Primary completion
Mar 31, 2022
Study completion Jul 1, 2022
Sponsor
- Lead sponsor
- MedRegen LLCIndustry
- Sponsor type
- Industry
- Collaborators
- ICON plc; Johns Hopkins University
- First posted
- Nov 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study consists of two parts. Part A (Phase I): A Phase I Double-blind Randomized Placebo-controlled Study in Healthy Subjects to Assess the Safety, Pharmacokinetics, Pharmacodynamics of MRG-001 Part B (Phase 2): A Phase IIa, Adaptive, Double-Blind, Randomized, Placebo-controlled, Multi-center Study in Hospitalized Patients Infected with Severe and Critical SARS-CoV-2 to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of MRG-001
Conditions
- COVID-19
- ARDS, Human
- Stem Cells
- Regeneration
Interventions
MRG-001Drug
Subjects will receive subcutaneous MRG-001 injections.
PlaceboDrug
Subjects will receive subcutaneous placebo injections.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: 60 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Johns Hopkins Medicine
Baltimore, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.